Zeptometrix

In the fast-evolving world of molecular diagnostics and life science research, accuracy and consistency are paramount. At ZeptoMetrix, we pride ourselves on providing cutting-edge solutions that empower laboratories, researchers, and clinicians worldwide. With decades of expertise and a commitment to excellence, we deliver high-quality tools, including advanced assay kits, quality controls, and specialized diagnostic reagents to ensure reliable and reproducible results.

One of our flagship products, the NATtrol Respiratory Verification Panel (RVP), is a cornerstone for laboratories conducting molecular testing for respiratory pathogens. This product serves as a reliable tool for validating and verifying qPCR and RT-PCR assays, ensuring optimal performance for critical diagnostic workflows.

Why the NATtrol Respiratory Verification Panel (RVP) is Essential

Respiratory pathogens,and other infectious agents, continue to pose global health challenges. Molecular techniques like quantitative PCR (qPCR) and RT-PCR are critical for accurately detecting and monitoring these pathogens. However, without proper quality controls, the reliability of results can be compromised.

The NATtrol RVP enables laboratories to:

Validate assay performance to meet the stringent demands.
Ensure accuracy and reproducibility in detecting a wide range of respiratory pathogens.
Optimize workflows by identifying variations or errors in RNA/DNA extraction, amplification, and analysis.
Meet regulatory compliance for molecular testing, ensuring adherence to standards for laboratory quality and precision.

Bridging Research and Clinical Diagnostics

At ZeptoMetrix, we recognize that molecular diagnostics is more than just science; it’s a lifeline for patients, clinicians, and researchers working to combat infectious diseases, discover new biomarkers, and advance medical knowledge. Our quality controls, including the NATtrol RVP, are trusted by laboratories worldwide to ensure robust results that drive impactful decisions.

In applications ranging from surveillance to genetic research and biomarker discovery, ZeptoMetrix tools enable groundbreaking discoveries and improved patient outcomes. By ensuring accuracy and consistency at every step, we empower laboratories to tackle global health challenges with confidence and precision.

The ZeptoMetrix Difference

Our mission is simple but powerful: to provide laboratories with solutions that enhance precision, improve efficiency, and enable success. With products like the NATtrol Respiratory Verification Panel, we are setting a new standard in molecular diagnostics, bridging the gap between cutting-edge research and real-world clinical applications.

Together, we can advance the frontiers of science, improve diagnostic accuracy, and make a meaningful impact. Partner with ZeptoMetrix—where innovation meets reliability.

Browse Zeptometrix Products

10X ELISA Wash Buffer

SKU: 0801060|Size: 125 mL

10X ELISA Wash Buffer (125 mL)

SKU: 801060|Size: 125 mL

ANTI HIV-1 P24 32/5.17.76

SKU: 0801124|Size: 1 mg

ANTI HTLV-I P24 46/3.24.4 1MG

SKU: 0801110|Size: 1 mg

ANTI HTLV-II GP46 73/4.9.8

SKU: 0801119|Size: 1 mg

ANTI HTLVII P24 75/4.21.11

SKU: 0801120|Size: 1 mg

ANTI-HIV1 GP41 CLONE 10E9

SKU: 0801121|Size: 1 mg

ANTI-HIV1 P17 CLONE 2D11

SKU: 0801122|Size: 1 mg

ANTI-PON1 CLONE KRJ1

SKU: 0801012|Size: 100 µg

ANTI-PON1 CLONE KRJ2

SKU: 0801014|Size: 100 µg

ANTI-ZIKA NS1 CLONE 1D12

SKU: 0801025|Size: 100 µg

ANTIHIV1 P17 CLN 32/5.8.42

SKU: 0801123|Size: 1 mg

ANTIHIV1 P24 CLN 38/8.7.47

SKU: 0801125|Size: 1 mg

ANTIHTLVI GP46 67/5.5.13.1

SKU: 0801127|Size: 1 mg

ANTIZIKA ENVLP CLONE 4C7

SKU: 0801026|Size: 100 µg

Adenovirus Rapid Test Control Pack

SKU: KZMC035|Size: 2x 1.5 mL

Anti-HIV Type 1 RT Clone 39/4.12.2

SKU: 0801128|Size: 1 mg

Anti-HIV Type 1 RT Clone 39/4.12.2 (1 mg)

SKU: 801128|Size: 1 mg

Anti-HIV Type 1 RT Clone 39/4.12.2 (100 ug)

SKU: 801007|Size: 100 µg

Anti-HIV Type 1 gp41 Clone 10E9

SKU: 0801006|Size: 100 µg

Anti-HIV Type 1 gp41 Clone 10E9 (1 mg)

SKU: 801121|Size: 1 mg

Anti-HIV Type 1 gp41 Clone 10E9 (100 ug)

SKU: 801006|Size: 100 µg

Anti-HIV Type 1 p17 Clone 2D11

SKU: 0801076|Size: 100 µg

Anti-HIV Type 1 p17 Clone 2D11 (1 mg)

SKU: 801122|Size: 1 mg

Anti-HIV Type 1 p17 Clone 2D11 (100 ug)

SKU: 801076|Size: 100 µg

Anti-HIV Type 1 p17 Clone 32/1.24.89

SKU: 0801077|Size: 100 µg

Anti-HIV Type 1 p17 Clone 32/1.24.89 (1 mg)

SKU: 801115|Size: 1 mg

Anti-HIV Type 1 p17 Clone 32/1.24.89 (100 ug)

SKU: 801077|Size: 100 µg

Anti-HIV Type 1 p17 Clone 32/5.8.42

SKU: 0801005|Size: 100 µg

Anti-HIV Type 1 p17 Clone 32/5.8.42 (1 mg)

SKU: 801123|Size: 1 mg

Anti-HIV Type 1 p17 Clone 32/5.8.42 (100 ug)

SKU: 801005|Size: 100 µg

Anti-HIV Type 1 p24 Clone 32/5.17.76

SKU: 0801078|Size: 100 µg

Anti-HIV Type 1 p24 Clone 32/5.17.76 (1 mg)

SKU: 801124|Size: 1 mg

Anti-HIV Type 1 p24 Clone 32/5.17.76 (100 ug)

SKU: 801078|Size: 100 µg

Anti-HIV Type 1 p24 Clone 38/8.7.47

SKU: 0801004|Size: 100 µg

Anti-HIV Type 1 p24 Clone 38/8.7.47 (1 mg)

SKU: 801125|Size: 1 mg

Anti-HIV Type 1 p24 Clone 38/8.7.47 (100 ug)

SKU: 801004|Size: 100 µg

Anti-HIV Type 1 p24 Clone 39/5.1.23 (1 mg)

SKU: 0801126|Size: 1 mg

Anti-HIV Type 1 p24 Clone 39/5.1.23 (100 µg)

SKU: 0801079|Size: 100 µg

Anti-HIV Type 1 p24 Clone 39/5.4A

SKU: 0801080|Size: 100 µg

Anti-HIV Type 1 p24 Clone 39/5.4A (1 mg)

SKU: 801136|Size: 1 mg

Anti-HIV Type 1 p24 Clone 39/5.4A (100 ug)

SKU: 801080|Size: 100 µg

Anti-HIV Type 1 p24 Clone 39/6.14

SKU: 0801081|Size: 100 µg

Anti-HIV Type 1 p24 Clone 39/6.14 (1 mg)

SKU: 0802014|Size: 1 mg

Anti-HIV Type 1 p24 Clone 39/6.14 (100 ug)

SKU: 801081|Size: 100 µg

Anti-HTLV Type I gp46 Clone 65/6C2.2.34

SKU: 0801094|Size: 1 mg

Anti-HTLV Type I gp46 Clone 65/6C2.2.34 (1 mg)

SKU: 801094|Size: 1 mg

Anti-HTLV Type I gp46 Clone 65/6C2.2.34 (100 µg)

SKU: 0802004|Size: 100 µg

Anti-HTLV Type I gp46 Clone 67/5.5.13.1

SKU: 0801084|Size: 100 µg

Anti-HTLV Type I gp46 Clone 67/5.5.13.1 (1 mg)

SKU: 801127|Size: 1 mg

Anti-HTLV Type I gp46 Clone 67/5.5.13.1 (100 ug)

SKU: 801084|Size: 100 µg

Anti-HTLV Type I gp46 Clone 68/4.11.21

SKU: 0801085|Size: 100 µg

Anti-HTLV Type I gp46 Clone 68/4.11.21 (1 mg)

SKU: 801118|Size: 1 mg

Anti-HTLV Type I gp46 Clone 68/4.11.21 (100 ug)

SKU: 801085|Size: 100 µg

Anti-HTLV Type I p19 Clone 45/6.11.1.3

SKU: 0801082|Size: 100 µg

Anti-HTLV Type I p19 Clone 45/6.11.1.3 (1 mg)

SKU: 801108|Size: 1 mg

Anti-HTLV Type I p19 Clone 45/6.11.1.3 (100 ug)

SKU: 801082|Size: 100 µg

Anti-HTLV Type I p19 Clone TP-7

SKU: 0801107|Size: 1 mg

Anti-HTLV Type I p19 Clone TP-7 (1 mg)

SKU: 801107|Size: 1 mg

Anti-HTLV Type I p19 Clone TP-7 (100 ug)

SKU: 801003|Size: 100 µg

Anti-HTLV Type I p24 Clone 46/3.24.4

SKU: 0801018|Size: 100 µg

Anti-HTLV Type I p24 Clone 46/3.24.4 (1 mg)

SKU: 801110|Size: 1 mg

Anti-HTLV Type I p24 Clone 46/3.24.4 (100 ug)

SKU: 801018|Size: 100 µg

Anti-HTLV Type II gp46 Clone 73/4.9.8

SKU: 0801086|Size: 100 µg

Anti-HTLV Type II gp46 Clone 73/4.9.8 (1 mg)

SKU: 801119|Size: 1 mg

Anti-HTLV Type II gp46 Clone 73/4.9.8 (100 ug)

SKU: 801086|Size: 100 µg

Anti-HTLV Type II p19 Clone 78/6.18.07

SKU: 0801113|Size: 1 mg

Anti-HTLV Type II p19 Clone 78/6.18.07 (1 mg)

SKU: 801113|Size: 1 mg

Anti-HTLV Type II p19 Clone 78/6.18.07 (100 ug)

SKU: 801093|Size: 100 µg

Anti-HTLV Type II p24 Clone 75/4.21.11

SKU: 0801087|Size: 100 µg

Anti-HTLV Type II p24 Clone 75/4.21.11 (1 mg)

SKU: 801120|Size: 1 mg

Anti-HTLV Type II p24 Clone 75/4.21.11 (100 ug)

SKU: 801087|Size: 100 µg

Anti-PON1 Clone KRJ1

SKU: 0801095|Size: 1 mg

Anti-PON1 Clone KRJ1 (1 mg)

SKU: 801095|Size: 1 mg

Anti-PON1 Clone KRJ1 (100 ug)

SKU: 801012|Size: 100 µg

Anti-PON1 Clone KRJ2 (1 mg)

SKU: 801097|Size: 1 mg

Anti-PON1 Clone KRJ2 (100 ug)

SKU: 801014|Size: 100 µg

Anti-Zika Envelope Clone 4C7 (100 ug)

SKU: 801026|Size: 100 µg

Anti-Zika NS1 Clone 1D12 (100 ug)

SKU: 801025|Size: 100 µg

Arylesterase/Paraoxonase Assay Kit

SKU: 0801199|Size: 200 Tests

Arylesterase/Paraoxonase Assay Kit (200 tests)

SKU: 801199|Size: 200 Tests

Bovine IgG ELISA

SKU: 0801198|Size: 96 Determinations

Bovine IgG ELISA (96 Determinations)

SKU: 801198|Size: 96 Determinations

Chicken IgY ELISA

SKU: 0801010|Size: 96 Determinations

Chicken IgY ELISA (96 Determinations)

SKU: 801010|Size: 96 Determinations

Coronavirus (Strain: 229E) Culture Fluid (Heat Inactivated) (1 mL)

SKU: 0810229CFHI|Size: 1 mL

Coronavirus (Strain: 229E) Culture Fluid (UV Inactivated) (1 mL)

SKU: 0810229UV|Size: 1 mL

Coronavirus (Strain: NL63) Culture Fluid (Heat Inactivated) (1 mL)

SKU: 0810228CFHI|Size: 1 mL

Coronavirus (Strain: NL63) Culture Fluid (UV Inactivated) (1 mL)

SKU: 0810228UV|Size: 1 mL

Coronavirus (Strain: OC43) Culture Fluid (Heat Inactivated) (1 mL)

SKU: 0810024CFHI|Size: 1 mL

EBV Seroconversion Panel Donor# 283843421 (14 X 1 mL)

SKU: EBV9097|Size: 14x 1 mL

ELISA Assay Diluent

SKU: 0801041|Size: 1 Unit

ELISA Construction System

SKU: 0801188|Size: 5x 96 Determinations

ELISA Construction System (5 X 96 Determinations)

SKU: 801188|Size: 5x 96 Determinations

ESR1 Control Kit

SKU: 0860016|Size: 1 Kit

GUINEAPIG IGG ELISA 96T/EA RUO

SKU: 0801029|Size: 96 Tests

Glutathione Reductase Assay Kit

SKU: 0805004|Size: 100 Tests

Goat Anti-SARS-CoV-2 Polyclonal Serum

SKU: 0801043|Size: 0.5 mL

Goat Anti-SARS-CoV-2 Polyclonal Serum, 0.5mL

SKU: 801043|Size: 0.5 mL

Goat IgG ELISA

SKU: 0801223|Size: 96 Determinations

Recent Breakthroughs

Metabolomic insights into Lyme neuroborreliosis: Exploring cerebrospinal fluid for diagnostic clues.

Kuukkanen I, Pietikäinen A, Rissanen T, Hurme S, Kortela E, Hytönen J, Karonen M.

Ticks Tick Borne Dis

PMID:42001681

Free PMC article

Lyme neuroborreliosis (LNB), a disseminated manifestation of Lyme borreliosis (LB), arises when Borrelia burgdorferi sensu lato (Bbsl) spirochetes disseminate within the host and damage the peripheral nervous system and meninges, and in rare cases, also the parenchyma of the central nervous system (CNS). While early-stage LB is diagnosed clinically, accurate diagnosis of LNB requires cerebrospinal fluid (CSF) analysis, demonstrating pleocytosis and intrathecal synthesis of Bbsl-specific antibodies. There are, however, limitations in current LNB diagnostics, such as the unspecific nature of pleocytosis and post-treatment persistence of intrathecal antibodies necessitating the search for novel biomarkers. In this study, we employed untargeted ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) to profile small metabolites (<1500 Da) in CSF samples from subjects with definite acute LNB. Comparative analyses of metabolite profiles were performed between pretreatment subject samples (n = 63) and the following groups: (A) a subset of samples collected three weeks after treatment initiation from the same individuals (n = 36), (B) Bbsl antibody-negative subjects (non-LNB, n = 61), (C) subjects with other CNS infections (n = 21). Additionally, pretreatment LNB samples were compared between individuals with radiculitis (n = 40) and those without radiculitis (n = 23) (D). Out of 4222 molecular features (MFs) detected, 131 were prioritized based on statistical significance and magnitude of change for further detailed structural characterization. Altered metabolite classes included compounds from lysophospholipids [e.g., lysophosphatidylcholine (16:0), and lysophosphatidylethanolamine (18:0)], sphingomyelins [e.g., sphingomyelin (d18:1/14:0) and sphingomyelin d16:1/16:0)], sphingoid bases (e.g., d19:0 sphinganine, and 3-ketosphingosine), fatty acid amides (e.g., palmitoleamide and oleamide), cyclic phosphatidic acids [i.e., cyclic phosphatidic acid (16:0) and cyclic phosphatidic acid (18:2)], and amino acid metabolism (i.e., DL-glutamine, 5-hydroxytryptophan and DL-kynurenine). These findings underscore the potential of CSF metabolomics as a powerful complementary tool for diagnosing LNB and differentiating it from other CNS conditions. The identified metabolic signatures offer a foundation for future biomarker development and may enhance diagnostic precision, guide treatment strategies, and deepen our understanding of LNB pathogenesis.

Isotope Dilution NanoLC-MS/MS Quantitation of Methylglyoxal DNA-Protein Cross-Links: Formation and Repair in Human Cells.

Omondi RO, Barnes EM, Gurajala KC, Fisette G, Chaudray IA, Erber L.

Anal Chem

PMID:41995195

Free PMC article

DNA-protein cross-links (DPCs) represent a prevalent form of DNA damage that forms when cellular proteins become covalently trapped to DNA strands upon exposure to various endogenous and exogenous agents. Methylglyoxal is an endogenous metabolite that reacts with guanine and adenine bases in DNA and RNA, as well as cysteine, arginine, and lysine residues in proteins, generating advanced glycation end-products (AGEs), including DPCs. These modifications have been linked to human disease, including cancer, liver disease, diabetes, and neurodegenerative disorders. Herein, we present a mass spectrometry method for quantifying MGO-induced DNA-protein cross-links (DPCs) in human cells. We prepared an isotope 15 N 2 13 C 6 -dG-MGO-Lys internal standard and developed a quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for detecting and quantifying the formation and repair of dG-MGO-Lys DPCs in cells. Genomic DNA was extracted, subjected to sequential protease and nuclease digestion, purified by offline high-performance liquid chromatography (HPLC), and analyzed by LC-MS/MS. The method's standard curve showed a strong linear relationship across a concentration range of 10-1000 fmol ( R 2 = 0.9994). The method achieved limits of detection (LOD) and quantification (LOQ) of 10 and 20 fmol, respectively. Inhibition of proteasome and SPRTN activity revealed that SPRTN functions as a predominant proteolytic enzyme in MGO DPC repair. Overall, this analytical approach can offer valuable insights into the relevance of DPCs in diseases linked to elevated MGO levels.

Label-Free High-Throughput Screening of CYP3A4 Inhibitors Using Acoustic Ejection Mass Spectrometry.

Rimmer MA, Wang J, Ranathunge TA, Shi Z, Li Y, Lee D, Chai SC, Lin W, Twarog NR, Ansari AZ, Shelat AA, Young BM, Chen T, Yang L.

Anal Chem

PMID:41997578

Free PMC article

Label-free high-throughput screening (HTS) technologies have greatly accelerated early drug discovery by allowing direct measurement of biochemical activity without the need for chemical labels. Techniques like MALDI-TOF, RapidFire, desorption electrospray ionization, and acoustic-mist ionization mass spectrometry have shown strong analytical performance. More recently, acoustic droplet ejection mass spectrometry (AEMS) has emerged as a next-generation platform capable of analyzing over a thousand data points per hour. In this study, we thoroughly evaluated an AEMS workflow using cytochrome P450 3A4 (CYP3A4) as a model enzyme. Screening a library of 9702 compounds, this work represents the first successful label-free HTS campaign for CYP3A4 inhibitors in a 384-well format using AEMS. The result using nifedipine as a substrate was comparable to the widely used P450-Glo luminescence assay but with fewer inhibitor hits identifications. To further compare and parse differences between the methods and the substrates, 819 hits were retested using AEMS with luciferin isopropyl acetal, the same substrate used in the luminescence assay. The findings confirmed that both the assay method and the substrate influence which inhibitors were detected. Overall, this study established AEMS as a robust and reliable tool for CYP3A4 inhibitor screening. It offers high analytical precision, fewer false positives, compatibility with multiple substrates, and direct detection of metabolites, providing a practical way to validate hits and improve confidence in early drug discovery efforts.

Quantification of the Active Metabolites 4-Methylaminoantipyrine and 4-Aminoantipyrine of Dipyrone From Human Plasma by LC-MS/MS.

Schmidt S, Ihmsen H, Golditz T, Schüttler J, Wehrfritz A.

Int J Anal Chem

PMID:42004449

Free PMC article

Dipyrone (metamizole) is widely used as a nonopioid analgesic in perioperative and intensive care settings; however, its administration may be associated with severe adverse effects. In this study, we describe an analytical assay for the quantification of the active metabolites 4-methylaminoantipyrine (4-MAA) and 4-aminoantipyrine (4-AA) in human plasma using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS). In addition, the protein-unbound fractions of both metabolites were determined by ultrafiltration. Chromatographic separation was performed on a UPLC system using gradient elution, followed by MS/MS detection with an electrospray ionization source. The limits of detection for both metabolites were 100 ng/mL. Across the investigated concentration range (100-10,000 ng/mL), the relative error (%RE) ranged from -6.3% to +3.5%. Intra-day and inter-assay variability were below 10%. Method validation was conducted in accordance with the 2018 FDA Bioanalytical Method Validation Guidance, and all evaluated parameters met the required criteria for analytical accuracy and precision. The developed assay is suitable for monitoring dipyrone metabolites and may support the prevention of potential overdosing during prolonged analgesic therapy or in intensive care settings.

Metabolomics profiling of acute myelogenous leukemia patients to identify systemic differences associated with in vitro sensitivity to SYK inhibitors.

Brattås MK, Hatfield KJ, Paulsen Rye K, Reikvam H.

Metabolomics

PMID:41995902

Free PMC article

Introduction Acute myelogenous leukemia (AML) is a heterogeneous hematological malignancy. Despite therapeutic advances, high relapse rates and poor survival persist, underscoring the need for new treatment strategies. Spleen tyrosine kinase (SYK) is crucial for leukemic cell survival and proliferation, and SYK inhibition is being explored in AML therapy. Objective This study aimed to identify whether distinct baseline serum metabolic profiles can differentiate between AML patient samples exhibiting high versus low in vitro sensitivity to SYK inhibition. Methods Leukemic cells from 49 AML patients were evaluated for their in vitro antiproliferative response to SYK-selective inhibitors (entospletinib, RO9021) and dual SYK/FLT3 inhibitors (fostamatinib, TAK-659). Serum samples from the same patients were subjected to untargeted metabolomic profiling using liquid chromatography-mass spectrometry (LC-MS). Bioinformatic analyses were applied to identify metabolic signatures associated with differential drug sensitivity. Results Hierarchical clustering identified three drug sensitivity groups, i.e. high, intermediate, low. Untargeted metabolomics identified 1204 metabolites across major pathways. Comparative analyses revealed distinct metabolic differences between patients with high versus low sensitivity to SYK inhibitors. For dual SYK/FLT3 inhibitors, lipid metabolites consistently were more discriminative for drug response, while for SYK selective inhibitors the profiles were more heterogeneous. Pathway analyses highlighted alterations in amino acid, lipid, and xenobiotic metabolism, including arginine biosynthesis and glycine/serine metabolism, as potential determinators for effect of SYK inhibition. Conclusion This study highlights potential metabolite signatures associated with in vitro SYK-targeted therapy in AML. These findings support future research to identify potential serum biomarkers, guiding personalized SYK inhibition strategies in AML.